<DOC>
	<DOCNO>NCT00101647</DOCNO>
	<brief_summary>The purpose clinical research study learn BMS-354825 activity , define hematologic response , subject accelerate phase chronic myeloid leukemia ( CML ) resistant intolerant imatinib mesylate . The safety treatment also study .</brief_summary>
	<brief_title>Study Dasatinib ( BMS-354825 ) Patients With Accelerated Phase Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Subjects Philadelphia chromosome positive ( PH+ ) fuse gene BCR/ABL positive ( BCR/ABL+ ) accelerate phase chronic myeloid leukemia ( CML ) whose disease primary acquire hematologic resistance imatinib mesylate intolerant imatinib mesylate . Subjects must prior exposure imatinib . However , imatinib mesylate need recent CML treatment prior come study . Men woman , 18 year age old . Adequate hepatic function . Adequate renal function . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study period least 1 month least 3 month study manner risk pregnancy minimize . Women pregnant breastfeeding . Subjects eligible willing undergo transplantation screen period . A serious uncontrolled medical disorder active infection would impair ability subject receive protocol therapy . Uncontrolled significant cardiovascular disease . Medications increase bleed risk . Medications change heart rhythm . Dementia alter mental status would prohibit understanding rendering informed consent . History significant bleeding disorder unrelated CML . Concurrent incurable malignancy CML . Evidence organ dysfunction digestive dysfunction would prevent administration study therapy . Prior therapy dasatinib ( BMS354825 ) . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Chronic myelogenous leukemia ( CML ) : Accelerated phase</keyword>
</DOC>